Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 5/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 5/20 | 0.44 |
| ▸ | S1PR5 | Q9H228 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16650233 | 0.89 | FKBP1A (0.46) | KMT2AMEN1TDP1ACE | |
| SCHEMBL991535 | 0.81 | TDP1 (0.55) | KMT2AMEN1TDP1L3MBTL1 | |
| SCHEMBL992344 | 0.78 | KMT2A (0.47) | KMT2AMEN1TDP1ALDH1A1 | |
| SCHEMBL992135 | 0.78 | POLB (0.61) | KMT2AMEN1TDP1L3MBTL1ALDH1A1 | |
| SCHEMBL1079065 | 0.76 | ALDH1A1 (0.57) | KMT2AMEN1TDP1L3MBTL1ALDH1A1 | |
| SCHEMBL19821665 | 0.75 | MEN1 (0.66) | KMT2AMEN1TDP1ALDH1A1 | |
| SCHEMBL991587 | 0.75 | ALDH1A1 (0.52) | KMT2AMEN1TDP1L3MBTL1ALDH1A1 | |
| SCHEMBL18013744 | 0.75 | TDP1 (0.73) | KMT2AMEN1TDP1L3MBTL1ALDH1A1 | |
| SCHEMBL14857112 | 0.74 | L3MBTL1 (0.45) | KMT2AMEN1L3MBTL1ACEACE2 | |
| SCHEMBL19821452 | 0.74 | MEN1 (0.64) | KMT2AMEN1TDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9782382-B2 | TOFA analogs useful in treating dermatological disorders or conditions | DERMIRA (CANADA), INC. (US) | 2017-10-10 | — | — | US | claimed |
| US-20160338988-A1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | DERMIRA (CANADA) INC (US) | 2016-11-24 | — | — | US | claimed |
| EP-2641906-B1 | Tofa analogs useful in treating dermatological disorders or conditions | DERMIRA CANADA INC (US) | 2015-04-22 | — | — | EP | claimed |
| US-8884034-B2 | TOFA analogs useful in treating dermatological disorders or conditions | DERMIRA (CANADA), INC. (US) | 2014-11-11 | — | — | US | claimed |
| EP-2641906-A1 | Tofa analogs useful in treating dermatological disorders or conditions | Dermira (Canada), Inc. (US) | 2013-09-25 | — | — | EP | claimed |
| EP-2451796-B1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | DERMIRA CANADA INC (US) | 2013-04-17 | — | — | EP | claimed |
| US-20120208807-A1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | Valocor Therapeutics, Inc. (CA) | 2012-08-16 | — | — | US | claimed |
| EP-2451796-A1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | Dermira (Canada), Inc. (CA) | 2012-05-16 | — | — | EP | claimed |
| WO-2011005660-A1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | Valocor Therapeutics, Inc. (CA) | 2011-01-13 | — | — | WO | claimed |
| WO-2022005871-A1 | METHODS OF TREATING SARS-COV-2 INFECTION USING INHIBITORS OF LIPOGENESIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-01-06 | — | — | WO | disclosed |
| US-9782382-B2 | TOFA analogs useful in treating dermatological disorders or conditions | DERMIRA (CANADA), INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20160338988-A1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | DERMIRA (CANADA) INC (US) | 2016-11-24 | — | — | US | disclosed |
| US-9434718-B2 | TOFA analogs useful in treating dermatological disorders or conditions | DERMIRA (CANADA), INC. (US) | 2016-09-06 | — | — | US | disclosed |
| EP-2641906-B1 | Tofa analogs useful in treating dermatological disorders or conditions | DERMIRA CANADA INC (US) | 2015-04-22 | — | — | EP | disclosed |
| US-8884034-B2 | TOFA analogs useful in treating dermatological disorders or conditions | DERMIRA (CANADA), INC. (US) | 2014-11-11 | — | — | US | disclosed |
| EP-2641906-A1 | Tofa analogs useful in treating dermatological disorders or conditions | Dermira (Canada), Inc. (US) | 2013-09-25 | — | — | EP | disclosed |
| EP-2451796-B1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | DERMIRA CANADA INC (US) | 2013-04-17 | — | — | EP | disclosed |
| US-20120208807-A1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | Valocor Therapeutics, Inc. (CA) | 2012-08-16 | — | — | US | disclosed |
| EP-2451796-A1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | Dermira (Canada), Inc. (CA) | 2012-05-16 | — | — | EP | disclosed |
| WO-2011005660-A1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | Valocor Therapeutics, Inc. (CA) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160338988-A1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | FAH, CUTA, ALOX5AP | KMT2A 2716/4885MEN1 4056/4885TDP1 3363/4885 |
| US-20120208807-A1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | FAH, CUTA, ALOX5AP | KMT2A 3026/4885MEN1 3929/4885TDP1 3323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.